Search Results
Your search for Matthew Stenger matches 297 pages
Showing 51 - 100Broad-Based Genomic Sequencing in Advanced NSCLC in the Community Oncology Setting
In a study reported in JAMA, Presley et al found that use of broad-based genomic sequencing vs routine testing for EGFR mutations or ALK rearrangements alone directed treatment in a minority of patients with advanced non–small cell lung cancer (NSCLC) in the community oncology setting and was ...
CNS Activity of EGFR Tyrosine Kinase Inhibitor in T790M-Positive Advanced NSCLC
In a planned subgroup analysis of the phase III AURA3 trial reported in the Journal of Clinical Oncology, Wu et al found that the third-generation EGFR tyrosine kinase inhibitor osimertinib (Tagrisso) produced higher central nervous system (CNS) response rates vs platinum plus pemetrexed (Alimta)...
Osimertinib Resistance Mechanisms in EGFR T790M–Positive NSCLC
In a study reported in JAMA Oncology, Oxnard et al found early resistance and a number of competing resistance mechanisms in acquired osimertinib (Tagrisso) resistance associated with loss of the T790M mutation conferring resistance to prior EGFR tyrosine kinase inhibitor (TKI) treatment in...
Adding Cisplatin to First-Line Treatment of Elderly Patients With Advanced NSCLC
A joint analysis of parallel phase III trials reported in the Journal of Clinical Oncology by Gridelli et al found no overall survival benefit of adding cisplatin to first-line treatment of elderly patients with advanced non–small cell lung cancer (NSCLC) without an EGFR mutation. Study...
Ado-Trastuzumab Emtansine in HER2-Mutant Lung Cancer
As reported by Li and colleagues in the Journal of Clinical Oncology, the HER2-targeted antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla) showed activity in advanced HER2-mutant lung adenocarcinoma. Study Details The current report involves a cohort of patients with HER2-mutant lung...
Biomarker-Integrated Risk Model for Lung Cancer
As reported in JAMA Oncology by the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium for Early Detection of Lung Cancer, incorporating biomarkers into a lung cancer risk prediction model may improve performance compared with risk based on age and smoking exposure alone....
Addition of Veliparib to Temozolomide in Recurrent Small Cell Lung Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Pietanza et al found no benefit of adding the PARP inhibitor veliparib to temozolomide (Temodar) in recurrent platinum-sensitive or platinum-refractory small cell lung cancer. Benefit was observed with the combination in the subgroup ...
ERBB Mutations and Outcomes With Afatinib and Erlotinib in Squamous NSCLC
In an analysis of the LUX-Lung 8 trial in squamous non–small cell lung cancer (NSCLC) reported in JAMA Oncology, Goss et al found that outcomes among patients treated with afatinib (Gilotrif) were better for those with vs without ERBB mutations. The LUX-Lung 8 trial showed that afatinib was...
Addition of Atezolizumab to Bevacizumab and Chemotherapy in First-Line Treatment of Metastatic Nonsquamous NSCLC
As reported at the 2018 ASCO Annual Meeting and in The New England Journal of Medicine by Socinski et al, the phase III IMpower150 trial has shown that the addition of atezolizumab (Tecentriq) to bevacizumab (Avastin) plus chemotherapy significantly improved progression-free and overall survival in ...
Final Overall Survival Analysis of First-Line Crizotinib vs Chemotherapy in Advanced ALK-Positive NSCLC
As reported by Solomon and colleagues in the Journal of Clinical Oncology, the final overall survival results of the phase III PROFILE 1014 trial showed evidence of survival benefit of first-line crizotinib (Xalkori) vs chemotherapy in advanced ALK-positive non–small cell lung cancer (NSCLC). ...
Prophylactic Cranial Irradiation in Stage III NSCLC
In a Dutch phase III trial reported in the Journal of Clinical Oncology, De Ruysscher et al found that prophylactic cranial irradiation (PCI) prevented symptomatic brain metastases vs observation in patients with stage III non–small cell lung cancer (NSCLC) receiving treatment with curative...
Lung Cancer Incidence in Young Women vs Men in the United States
In a study reported in The New England Journal of Medicine, Jemal et al found that the incidence of lung cancer in young white and Hispanic women is now higher than that in men in the US. Study Details The study involved analysis of data from the North American Association of Central Cancer...
Characteristics and Screening of Brain Metastases in Breast Cancer and NSCLC
In a research letter published in JAMA Oncology, Cagney et al found that brain metastases were more advanced and more likely to be symptomatic in patients with breast cancer compared to patients with non–small cell lung cancer (NSCLC). Current guidelines recommend magnetic resonance imaging...
Analysis of Intracranial Response to Brigatinib in ALK-Positive NSCLC With Brain Metastases
In an analysis of two clinical trials reported in the Journal of Clinical Oncology, Camidge et al found that brigatinib (Alunbrig) produced high intracranial response rates and good intracranial progression-free survival in patients with ALK-positive non–small cell lung cancer (NSCLC) and...
Safety of PD-1/PD-L1 Inhibitors in Patients With NSCLC and Preexisting Autoimmune Disorders
In a study reported in the Journal of Clinical Oncology, Leonardi et al found that programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitor monotherapy in patients with non–small cell lung cancer (NSCLC) and autoimmune disorders worsened such disorders in a...
Survival in Male vs Female Patients Receiving Immune Checkpoint Inhibitors
In a systematic review and meta-analysis reported in The Lancet Oncology, Conforti et al found a significant difference in overall survival benefit favoring male vs female patients receiving immune checkpoint inhibitor therapy for advanced cancers. Study Details The study involved database...
NGR-hTNF Combined With Investigator Choice of Therapy in Previously Treated Malignant Pleural Mesothelioma
In the phase III NGR015 trial reported in The Lancet Oncology, Gregorc et al found no benefit of adding NGR-hTNF to best investigator choice of treatment in patients with previously treated malignant pleural mesothelioma. NGR-hTNF consists of human TNFα conjugated to the tumor-targeting ...
IL-15 Superagonist Plus Nivolumab in Advanced NSCLC
In a phase Ib trial reported in The Lancet Oncology, Wrangle et al found evidence of activity of the combination of nivolumab (Opdivo) and the interleukin (IL)-15 superagonist ALT-803 in patients with previously treated advanced non–small cell lung cancer (NSCLC). ALT-803 targets the shared...
Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC
In a phase II study reported in the Journal of Clinical Oncology, Wu et al found that crizotinib (Xalkori) was highly active in East Asian patients with ROS1-positive advanced non–small cell lung cancer (NSCLC). Study Details In the study, 127 patients from 37 sites in China, Japan,...
AACR 2018: Pilot Study of Neoadjuvant Nivolumab in Resectable NSCLC
In a pilot study reported at the 2018 American Association for Cancer Research (AACR) Annual Meeting (Abstract CT079) and in The New England Journal of Medicine by Forde et al, neoadjuvant nivolumab therapy was found to be feasible and active in patients with resectable non–small cell lung...
AACR 2018: KEYNOTE-189: Addition of Pembrolizumab to Chemotherapy in Metastatic NSCLC
As reported at the American Association for Cancer Research (AACR) Meeting (Abstract CT075) in the The New England Journal of Medicine by Gandhi et al, the first interim analysis of the phase III KEYNOTE-189 trial has shown significant improvement in overall and progression-free survival with the...
AACR 2018: CheckMate 227: Nivolumab/Ipilimumab vs Chemotherapy in NSCLC With High Tumor Mutational Burden Analysis
As reported at the 2018 American Association for Cancer Research (AACR) Meeting (Abstract CT077) and in The New England Journal of Medicine by Hellmann et al, an analysis from the phase III CheckMate 227 trial has shown that the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy)...
5-Year Follow-up of Patients Receiving Immunotherapy for Previously Treated Advanced NSCLC
As reported in the Journal of Clinical Oncology by Gettinger et al, 5-year follow-up of patients receiving nivolumab (Opdivo) in a phase I study (CA209-003) in previously treated advanced non–small cell lung cancer (NSCLC) has shown prolonged survival and durable responses in a subgroup...
Fruquintinib in Pretreated Advanced NSCLC
In a Chinese phase II trial reported in the Journal of Clinical Oncology, Lu et al found that the VEGFR-1,-2, and-3 kinase inhibitor fruquintinib was active in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) who progressed after two prior chemotherapy regimens. Study Details ...
Immunotherapy in Heavily Pretreated Advanced NSCLC
As reported in The Lancet Oncology by Garassino et al, the phase II ATLANTIC trial has shown durvalumab (Imfinzi) to be active in third- or later-line treatment of advanced non–small cell lung cancer (NSCLC). Study Details In the study, 444 patients from 139 sites in Asia, Europe, and North ...
ASCO Endorses CAP/IASLC/AMP Guideline Update on Molecular Testing for Targeted Tyrosine Kinase Inhibitor Treatment in Lung Cancer
As reported in the Journal of Clinical Oncology by Gregory P. Kalemkerian, MD, and colleagues, ASCO has endorsed the College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) updated guideline on molecular...
ALK Variant, Resistance, and Clinical Outcomes in ALK-Positive NSCLC
In a study reported in the Journal of Clinical Oncology, Lin et al found that specific ALK variants may be associated with the development of resistance mutations to ALK tyrosine kinase inhibitors (TKIs) in ALK-positive non–small cell lung cancer (NSCLC). Study Details The study involved...
ASCO Clinical Practice Guideline: Treatment of Malignant Pleural Mesothelioma
As reported by Hedy L. Kindler, MD, of the University of Chicago, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline on treatment of malignant pleural mesothelioma. The guideline was informed by a systematic literature search and expert panel review ...
Posttreatment Mortality With Stereotactic Body Radiotherapy vs Surgery in NSCLC
In a study reported in the Journal of Clinical Oncology, Stokes and colleagues found lower posttreatment mortality rates with stereotactic body radiotherapy (SBRT) vs surgery in early-stage non–small cell lung cancer (NSCLC), with the difference in rates increasing as a function of age....
Barriers to Treatment in Limited-Stage Small Cell Lung Cancer
In a study reported in JAMA Oncology, Pezzi et al found that lack of health insurance, including Medicare and Medicaid, was associated with not receiving combined-modality therapy in limited-stage small cell lung cancer (SCLC). They also found that lack of insurance was associated with poorer...
Passive Scattering Proton Therapy vs Intensity-Modulated Photon Radiotherapy for Locally Advanced NSCLC
In a study reported in the Journal of Clinical Oncology, Liao et al found that passive scattering proton radiotherapy (PSPT) improved heart—but not lung—radiation dose-volume indices vs intensity-modulated photon radiotherapy (IMRT) in patients with advanced non–small cell lung...
Sequence of Postoperative Radiotherapy and Chemotherapy in Locally Advanced or Incompletely Resected NSCLC
In a study of National Cancer Database data reported in the Journal of Clinical Oncology, Francis et al found that receipt of adjuvant chemotherapy before vs concurrently with radiotherapy was associated with improved survival in patients with non–small cell lung cancer (NSCLC) found to have...
Combination Therapy for Previously Untreated Stage IV NSCLC
As reported in The Lancet Oncology by Herbst et al, the phase III SWOG S0819 trial showed no overall benefit of adding cetuximab (Erbitux) to carboplatin/paclitaxel both with and without bevacizumab (Avastin) in patients with previously untreated stage IV non–small cell lung cancer (NSCLC). A ...
EU Expert Group Releases Position Statement on Lung Cancer Screening in Europe
As reported in The Lancet Oncology by Oudkerk et al, a European Union (EU) expert group has issued a position statement on low-dose computed tomography (CT) screening for lung cancer, proposing a near-term phased implementation of screening in high-risk regions within 18 months and extension to all ...
Comparison of EGFR Inhibitors in Untreated Advanced EGFR-Mutant NSCLC
As reported in The New England Journal of Medicine by Soria et al, the phase III FLAURA trial has shown a significant progression-free survival benefit with the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib (Tagrisso) vs standard EGFR TKIs in...
Adjuvant Chemotherapy With or Without Monoclonal Antibody in Resected NSCLC
The phase III E1505 trial has shown no benefit of adding bevacizumab (Avastin) to adjuvant therapy in early-stage resected non–small cell lung cancer (NSCLC). These results were reported by Wakelee et al in The Lancet Oncology. Study Details In the open-label trial, 1,501 patients from...
Patient-Reported Outcomes With Immunotherapy vs Chemotherapy in Advanced NSCLC
Pembrolizumab (Keytruda) treatment was associated with improved or maintained health-related quality of life vs platinum-based chemotherapy in the phase III KEYNOTE-024 trial in advanced programmed cell death ligand 1 (PD-L1)–positive non–small cell lung cancer (NSCLC). These findings...
ASCO Endorses ASTRO Guideline on Stereotactic Body Radiotherapy for Early-Stage NSCLC
As reported in the Journal of Clinical Oncologyby Bryan J. Schneider, MD, of the University of Michigan, Ann Arbor, and colleagues, ASCO has endorsed the recently released American Society for Radiation Oncology (ASTRO) evidence-based guideline on stereotactic body radiotherapy in early-stage...
Novel Tyrosine Kinase Inhibitor for ALK- or ROS1-Rearranged NSCLC
A phase I trial has shown that the ALK and ROS1 tyrosine kinase inhibitor lorlatinib is active in patients with advanced ALK- or ROS1-positive non–small cell lung cancer (NSCLC), including those with central nervous system (CNS) metastases and failure on at least two prior tyrosine kinase...
PanCan Risk Model for Lung Cancer Screening
Results of the Pan-Canadian Early Detection of Lung Cancer (PanCan) study, reported in The Lancet Oncology by Tammemagi et al, indicate that the PanCan risk model is effective in identifying persons found to have early-stage lung cancer on low-dose computed tomography (CT) screening. Study Details ...
2-Year Survival Outcomes With Immunotherapy in Advanced NSCLC
Analysis of 2-year overall survival with nivolumab (Opdivo) vs docetaxel in the phase III CheckMate 017 and 057 trials showed a continued survival benefit with nivolumab in patients with previously treated advanced non–small cell lung cancer (NSCLC). The findings were reported by Horn et al...
Outcomes in Patients With Metastatic Lung Cancer Receiving PD-1/PD-L1 Inhibitors With Thoracic Radiotherapy
In a research letter to JAMA Oncology, Hwang et al detailed the outcomes of patients with metastatic lung cancer receiving an inhibitor of programmed cell death protein 1 (PD-1) or its ligand (PD-L1) with or without thoracic radiotherapy at Massachusetts General Hospital. Study Details The...
Addition of EGFR Tyrosine Kinase Inhibitor to Chemotherapy in Resistant Non–Small Cell Lung Cancer
As reported by Mok et al in the Journal of Clinical Oncology, overall survival analysis of the phase III IMPRESS trial indicated a poorer outcome when adding gefitinib (Iressa) vs placebo to chemotherapy after disease progression on first-line gefitinib in epidermal growth factor receptor...
Immune-Related Adverse Events and Outcomes With Immunotherapy for NSCLC
In a Japanese analysis reported in JAMA Oncology, Haratani et al found that development of immune-related adverse events was associated with improved survival among patients receiving nivolumab (Opdivo) for advanced or recurrent non–small cell lung cancer (NSCLC). Study Details The study...
Comparison of First-Line Treatments for EGFR-Mutant NSCLC
The phase III ARCHER 1050 trial has shown superior progression-free survival with the second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor dacomitinib vs gefitinib (Iressa) in the first-line treatment of advanced EGFR-mutant non–small cell lung...
Consolidative Radiotherapy for Limited Metastatic NSCLC
In a single-institution phase II trial reported in JAMA Oncology, Iyengar et al found that consolidative stereotactic ablative radiotherapy improved progression-free survival vs maintenance therapy alone in patients with limited metastatic non–small cell lung cancer (NSCLC). Study Details...
Combination Therapy for Previously Untreated BRAF V600E–Mutant Metastatic NSCLC
In a phase II trial, the combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) produced durable responses in a cohort of patients with previously untreated BRAF V600E–mutant metastatic non–small cell lung cancer (NSCLC). The findings were reported in The Lancet Oncology by...
MicroRNA-Loaded Minicells in Recurrent Malignant Pleural Mesothelioma
An Australian phase I first-in-human trial has shown early activity of microRNA-loaded minicells in patients with malignant pleural mesothelioma. These findings were reported in The Lancet Oncology by van Zandwijk et al. The minicells (TargomiRs) are loaded with miR-16–based mimic microRNA...
Addition of Motesanib to Paclitaxel/Carboplatin in East Asian Patients With Advanced NSCLC
The phase III MONET-A trial has shown that the addition of the multikinase/vascular endothelial growth factor receptor inhibitor motesanib to paclitaxel and carboplatin did not significantly improve progression-free survival in East Asian patients with stage IV/recurrent nonsquamous non–small ...
Durvalumab Consolidation After Chemoradiotherapy in Stage III NSCLC
As reported by Antonia et al in The New England Journal of Medicine, an interim analysis of the phase III PACIFIC trial showed improved progression-free survival with the programmed cell death protein 1 (PD-1) inhibitor durvalumab (Imfinzi) vs placebo as consolidation in patients with unresectable...
